The ARCHER trial is seeking to determine whether ultra-hypofractionated radiotherapy is non-inferior to hypofractionated radiotherapy in terms of bladder-intact event-free survival.
Sandip M. Prasad, MD, MPhil, details key findings from the phase 3 ENVISION trial, which supported the approval of mitomycin intravesical solution in LG-IR-NMIBC.
Purpose:We aimed to determine if, using baseline MRI-guided biopsy (MRGB), durability of active surveillance (AS) could be predetermined, follow-up biopsies avoided, and if by incorporating…
Purpose:The efficacy of ureteroscopy to treat urinary stones is often less than 60%. Acoustic Enhancer is an investigational device of microparticles with a tag designed…
This is the first randomized trial to investigate metastasis-directed therapy plus continuous androgen deprivation therapy for oligometastatic prostate cancer.
According to the authors, these data support the value of PSMA PET/CT in the pre-salvage radiotherapy selection process.
Suzanne B. Merrill, MD, FACS, unpacks key findings from the CREST trial and outlines data of interest from the POTOMAC and PATAPSCO trials, which are…
Purpose:Genitourinary syndrome of menopause (GSM) describes the symptoms and physical changes that result from declining estrogen and androgen concentrations in the genitourinary tract during the…
This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Read our Cookies
Aleece Fosnight, MSPAS, PA-C, CSC-S, CSE, IF, MSCP, HAES, emphasizes a careful, individualized approach to managing bladder and bowel symptoms in women with a history…
The EAU Guidelines Panel for Muscle-invasive and Metastatic Bladder Cancer (MIBC) have prepared these guidelines to help urologists assess the evidence-based management of MIBC and…
